CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Shanghai Fosun Pharmaceutical (Group) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Shanghai Fosun Pharmaceutical (Group)
Building A, No.1289 Yishan Road
Phone: +86 2133987870p:+86 2133987870 SHANGHAI, SHA  200233  China Ticker: 600196600196
Business Summary
Shanghai Fosun Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the research and development, manufacturing and sales of pharmaceutical products. The Company operates in five segments. Pharmaceutical segment is mainly engaged in the manufacturing of innovative drugs, mature pharmaceutical products and vaccines. Medical Devices and Medical Diagnostics segment is mainly engaged in the manufacturing and sales of medical cosmetic devices such as molecular diagnosis, immunodiagnosis, and microbial diagnosis. Medical Health Services segment is mainly engaged in the operation of an online and offline integrated medical service platform. Pharmaceutical Distribution and Retail segment is mainly engaged in the wholesale and retail of pharmaceutical products. Others segment is engaged in other pharmaceutical-related businesses. The Company's products are mainly used in the treatment of tumors, immunity, central nervous system and other fields.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
3841 Surgical and medical instruments and apparatus
2835 In vitro and in vivo diagnostic substances
8099 Health and allied services, not elsewhere classified
3845 Electromedical and electrotherapeutic apparatus
8062 General medical and surgical hospitals
5122 Drugs, drug proprietaries, and druggists' sundries
5912 Drug stores and proprietary stores

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board YifangWu 54 6/1/2022 6/8/2016
Executive Co-Chairman of the Board KexinWang 59 6/1/2022 7/1/2011
Executive President, Chief Human Resource Officer, Senior Vice President RongliFeng 48 1/17/2024 3/5/2021
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Breas Medical AB Företagsvägen 1 Sweden
Gland Pharma Limited 1 Cabela Drive Hyderabad India
Fosun Pharma USA, Inc. 104 Carnegie Center, Suite 204 Princeton NJ United States

Business Names
Business Name
2196
600196
Breas Medical AB
5 additional Business Names available in full report.

General Information
Number of Employees: 40,370 (As of 12/31/2023)
Outstanding Shares: 2,665,524,965 (As of 11/1/2024)
Shareholders: 298,973
Stock Exchange: SHA
Fax Number: +86 2133987871


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024